Skip to content
DataLookout
Menu

RESERVIH32NCT03940521

Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment

StatusCompleted
PhaseNot specified
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 13 words Show 4 more changesShow less
    • Trial completed
    • Final enrollment: 30 participants (planned 48)
    • Study completion date changed from estimate of Sep 2026 to Sep 24, 2026
    • Secondary endpoints: details revised at 14 of 19 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Sep 2025 to Sep 30, 2025
    • Site details revised
    v12
  3. Notable Primary completion date: Sep 2024 to Sep 2025
    • Study completion date: Sep 2025 to Sep 2026
    • Site contact updated
    v11
  4. Minor Study completion date: Sep 2024 to Sep 2025
    • Secondary endpoints: 17 to 19
    v10
  5. Notable Primary and study completion dates: Sep 2023 to Sep 2024v9
Show 7 earlier versionsHide 7 earlier versions
  1. Notable Primary and study completion dates: Sep 2022 to Sep 2023v8
  2. Minor Primary and study completion dates: Jun 2022 to Sep 2022v7
  3. Notable Primary and study completion dates: Jun 2021 to Jun 2022v6
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 2020 to Sep 30, 2020
    • Site details revised
    v5
  5. Notable Start date: Feb 2020 to Sep 2020
    • Primary and study completion dates: Dec 2020 to Jun 2021
    v4
  6. Notable Start date: Sep 2019 to Feb 2020
    • Primary and study completion dates: Sep 2020 to Dec 2020
    v3
  7. Notable Start date: May 2019 to Sep 2019
    • Primary and study completion dates: May 2020 to Sep 2020
    • Collaborator revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percentage of CD4+ T cells expressing CD32 alone
Timeframe: Day 0
Percentage of CD4+ T cells expressing X alone
Timeframe: Day 0
Percentage of CD4+ T cells expressing both CD32 and X
Timeframe: Day 0
Quantification of proviral load
Timeframe: Day 0

Secondary (19)

Duration of infection prior to treatment
Duration of treatment
Year treatment commenced
Pre-therapeutic CD4 + T cell count
Pre-therapeutic viremia
Show 14 moreShow less
Change in CD4+ T cells over previous 2 years
Change in CD4+ T cells prior to treatment
Change in CD4+ T cells during treatment
Viremia at inclusion into the study
Viremia during the 2 previous years
Residual immune activation at inclusion into the study
Residual immune activation during the previous 2 years
Nature of current treatment
Co-infection with hepatitis C virus
Co-infection with hepatitis B virus
Co-infection with Cytomegalovirus
Co-infection with Epstein-Barr virus
Testing for intact proviral DNA
Circulating viral RNA sequence

Arms and interventions

HIV-A infected patients

Other: Bioclinical evaluation

Sites

1 site in 1 country

  • CHU de NimesNîmes, France